

Jubilant FoodWorks

Refer to important disclosures at the end of this report

Growth to accelerate after Q1 lockdown impact

- JUBI's Q4 performance missed our expectations, with EBITDA/PAT coming in lower by 14%/8%, largely driven by lower margins due to higher overhead spends. Sales recovery was largely in line, with topline growth of 14% on SSG of 11.8%.
- Despite lockdowns, Apr-May'21 recovery at ~90% (vs. FY20) has been impressive, indicating strong traction in delivery. JUBI added 134 Dominos stores in FY21 (one-off 109 store closures) and expects expansion to be similar in FY22.
- Margins were up 540bps yoy but missed expectations on higher overheads (Covid-related spends and marketing spends). Management expects to sustain margins levels; will expand new formats (Hongs/Ekdum/Popeye) in a calibrated manner.
- Gains from stronger digital/delivery capabilities, aggressive store expansion and new formats offer a stronger growth outlook. Hence, we raise the target multiple to 55x from 50x and roll over to Sep'23E EPS. Maintain Buy with a revised TP of Rs3,400 (Rs2,750 earlier).

SSG at 11.8%; Apr-May'21 recovery encouraging despite lockdowns: Revenues grew 14.3% in Q4, led by 11.8% SSG and increase in stores (1,360 stores vs. 1,335 a year ago). Despite recent lockdowns April-May'21, recovery was ~90% of pre-Covid levels (vs. 40% recovery in first lockdown), indicating lower lockdown impact and strong traction in delivery. New store additions were higher at 50 stores for the 2nd consecutive quarter vs. quarterly average of 25-30 stores. Higher store openings impacted Q4 SSG due to stores being split. Adjusted for this, LFL growth was 15.1%. JUBI added 134 gross stores in FY21 and expects similar openings in FY22 as well. Among channels, Delivery/Takeaway channels (~70% of sales) saw ~29%/77% growth, while Dine-in (~30% of sales) remained on the recovery path (64% recovery in Q4 vs. 42%/18%/2% in Q1/Q2/Q3). With Popeyes, management expects a large growth opportunity in fast-growing ~Rs40bn chicken market.

Margins miss on higher overheads; expect some improvement ahead: EBITDA margins were up 540bps yoy to 24.3% (~200bps lower qoq) but missed expectations on lower gross margins (-80bps qoq) and higher other expenses (up 250bps). Employee costs were largely flat yoy. Gross margin decline was led by RM Inflation (cheese) and higher other expenses as a result of higher new store openings and Covid-19-related expenses. Going ahead, it expects to sustain EBITDA margins, with plans to expand new formats in a calibrated manner.

Growth outlook remains encouraging; maintain Buy: Despite margin miss, JUBI continues to provide a strong earnings growth outlook, and higher SSG/store expansions can still drive upsides. Domino's strong digital/delivery capabilities, faster store additions and new formats offer plenty of reasons to remain positive. We raise the target multiple to 55x from 50x and roll over to Sep'23E EPS. Maintain Buy with a TP to Rs3,400 (vs Rs2750 earlier).

Please see our sector model portfolio (Emkay Alpha Portfolio): [Consumer Goods & Retail \(page 8\)](#)

Financial Snapshot (Standalone)

(Rs mn)	FY20	FY21	FY22E	FY23E	FY24E
Revenue	38,858	32,689	44,710	55,500	64,514
EBITDA	8,771	7,666	11,436	14,599	17,041
EBITDA Margin (%)	22.6	23.5	25.6	26.3	26.4
APAT	3,203	2,337	5,066	7,136	8,555
EPS (Rs)	24.3	17.7	38.4	54.1	64.8
EPS (% chg)	(3.1)	(27.0)	116.8	40.9	19.9
ROE (%)	25.6	17.4	32.0	37.5	35.5
P/E (x)	130.9	179.4	82.7	58.7	49.0
EV/EBITDA (x)	47.0	53.9	36.0	27.8	23.4
P/BV (x)	35.4	28.0	25.1	19.6	15.6

Source: Company, Emkay Research

CMP	Target Price
Rs 3,176 as of (June 15, 2021)	Rs 3,400 (▲) 12 months
Rating	Upside
BUY (■)	7.1 %

Change in Estimates	
EPS Chg FY22E/FY23E (%)	(14)/(1)
Target Price change (%)	23.6
Target Period (Months)	12
Previous Reco	BUY


Emkay vs Consensus

EPS Estimates		
	FY22E	FY23E
Emkay	38.4	54.1
Consensus	39.2	49.8
Mean Consensus TP (12M)	Rs 2,995	

Stock Details	
Bloomberg Code	JUBI IN
Face Value (Rs)	10
Shares outstanding (mn)	132
52 Week H/L	3,252 / 1,596
M Cap (Rs bn/USD bn)	419 / 5.72
Daily Avg Volume (nos.)	6,19,234
Daily Avg Turnover (US\$ mn)	24.9

Shareholding Pattern Mar '21	
Promoters	41.9%
FII	40.9%
DII	11.4%
Public and Others	5.8%

Price Performance				
(%)	1M	3M	6M	12M
Absolute	13	7	23	87
Rel. to Nifty	5	1	5	16



Source: Bloomberg

This report is solely produced by Emkay Global. The following person(s) are responsible for the production of the recommendation:

Ashit Desai

ashit.desai@emkayglobal.com

+91 22 6612 1340


Devanshu Bansal

devanshu.bansal@emkayglobal.com

+91 22 6612 1385


Story in Charts

Exhibit 1: Faster recovery has been led by strong traction in delivery/takeaway, while dine-ins remain impacted




Source: Company, Emkay Research

Exhibit 3: Gross margins remained elevated YoY; QoQ margin decline was led by RM inflation and higher other expenses




Source: Company, Emkay Research

Exhibit 5: Healthy improvement in own app downloads




Source: Company, Emkay Research

Exhibit 2: Store additions for Dominos were healthy at 50 new additions; store additions are expected to remain aggressive




Source: Company, Emkay Research

Exhibit 4: Domino's entered into 11 new cities vs Q4FY20




Source: Company, Emkay Research

Exhibit 6: JUBI's 1-Yr fwd PE chart



Source: Company, Emkay Research

Exhibit 7: April-May'21 recovery is healthy at 90% vs. ~40% recovery during first lockdown



Source: Company, Emkay Research

Exhibit 8: Actual vs estimates (Q4FY21)

	Actual	Emkay estimate	Consensus estimate	% variation		Comment
				Emkay	Consensus	
Revenues	10,259	10,603	10,434	-3.2%	-1.7%	Slight revenue miss due to lower SSG from split stores
EBITDA	2,492	2,902	2,712	-14.1%	-8.1%	
EBITDA Margin (%)	24.3%	27.4%	26.0%	-308	-170	Margins impacted by higher overhead spends
APAT	1,043	1,297	1,074	-19.6%	-2.9%	

Source: Company, Emkay Research

Exhibit 9: Quarterly financials

Y/E Mar (Rs mn)	Q4FY20	Q1FY21	Q2FY21	Q3FY21	Q4FY21	YoY (%)	QoQ (%)	FY20	FY21	YoY (%)
Total income	8,979	3,803	8,055	10,572	10,259	14.3	(3.0)	38,858	32,689	(15.9)
Gross Profit	6,682	2,967	6,346	8,278	7,947	18.9	(4.0)	29,151	25,539	(12.4)
Employee expenses	1,960	1,499	1,666	2,196	1,997	1.9	(9.0)	7,846	7,357	(6.2)
as % of sales	22%	39%	21%	21%	19%				20%	23%
Rent	212	-204	27	74	213	0.5	187.2	828	111	(86.6)
as % of sales	2%	-5%	0%	1%	2%				2%	0%
Other expenses	2,815	1,431	2,507	3,222	3,245	15.3	0.7	11,705	10,405	(11.1)
as % of sales	31%	38%	31%	30%	32%				30%	32%
EBITDA	1,694	241	2,147	2,786	2,492	47.1	(10.6)	8,771	7,666	(12.6)
Depreciation & Amortization	916	908	1,030	876	858	(6.3)	(2.1)	3,441	3,672	6.7
EBIT	778	-667	1,117	1,910	1,634	109.9	(14.5)	5,330	3,993	(25.1)
Interest cost	410	419	412	405	370	(9.6)	(8.6)	1,635	1,606	
Other income	204	127	311	156	110	(46.2)	(29.4)	688	704	2.2
Exceptional items	323	0	0	0	0			448	0	
PBT	250	-959	1,016	1,661	1,373	449.8	(17.3)	3,935	3,091	(21.5)
Tax	39	-233	247	410	330	738.9	(19.4)	1,181	754	
Net Profit	210	-726	769	1,251	1,043	395.7	(16.6)	2,755	2,337	(15.2)
Adj Profit	533	-726	769	1,251	1,043	95.6	(16.6)	3,203	2,337	(27.0)
EPS (Rs)	4.0	-5.5	5.8	9.5	7.9	95.6	(16.6)	24.3	17.7	(27.0)

Margins (%)	Q4FY20	Q1FY21	Q2FY21	Q3FY21	Q4FY21	YoY (%)	QoQ (%)	FY20	FY21	YoY (%)
Gross Margin	74.4	78.0	78.8	78.3	77.5	300 bps	(80 bps)	75.0	78.1	310 bps
EBITDA	18.9	6.3	26.7	26.4	24.3	540 bps	(210 bps)	22.6	23.5	90 bps
EBIT	8.7	-17.5	13.9	18.1	15.9	730 bps	(210 bps)	13.7	12.2	(150 bps)
PAT	2.3	-19.1	9.5	11.8	10.2	780 bps	(170 bps)	7.1	7.1	10 bps
Tax rate (%)	15.8	24.3	24.3	24.7	24.0	830 bps	(60 bps)	30.0	24.4	(560 bps)

Source: Company, Emkay Research

Exhibit 10: Peer Comparison

Companies	Price (Rs)	Mcap (Rs bn)	Reco	Target Price (Rs)	EPS (Rs)			P/E (x)			EV / EBITDA (x)		
					FY22E	FY23E	FY24E	FY22E	FY23E	FY24E	FY22E	FY23E	FY24E
ABFRL	208	192	Buy	210	2.6	3.7	4.8	81.2	56.2	43.4	13.4	11.2	9.7
Jubilant FoodWorks	3,176	423	Buy	3,400	38.4	54.1	64.8	83.6	59.3	49.5	36.3	28.1	23.6
Page Industries	30,221	337	Buy	36,500	475.9	629.6	737.1	63.5	48.0	41.0	42.8	33.0	28.2
Shoppers Stop	236	26	Hold	230	-7.8	6.9	-17.7	-30.1	34.1	-13.3	18.5	7.1	10.5
Titan Company	1,739	1,544	Buy	1,725	25.6	32.8	39.1	67.9	53.0	44.5	43.6	34.5	28.8
Westlife Development	496	77	Buy	600	0.0	4.0	6.4	NA	123.4	77.2	39.8	24.2	19.5

Source: Company, Emkay Research

Exhibit 11: Revision in estimates

Y/E, Mar (Rs. mn)	FY22E			FY23E			FY24E
	Earlier	Revised	% Change	Earlier	Revised	% Change	Introduced
Revenues	46,220	44,710	-3.3	53,857	55,500	3.1	64,514
EBITDA	12,402	11,436	-7.8	14,562	14,599	0.3	17,041
EBITDA Margin (%)	26.8	25.6	-130 bps	27.0	26.3	-70 bps	26.4
APAT	5,890	5,066	-14.0	7,192	7,136	-0.8	8,555
EPS (Rs)	44.6	38.4	-14.0	54.5	54.1	-0.8	64.8

Source: Company, Emkay Research

Con-call Highlights

- **March data leak:** JUBI did not indicate any impact on operations due to data breach. JUBI has appointed a global forensic agency to identify the deficiencies and prevent recurrence of such events.
- JUBI vaccinated close to 14,500 employees with first dose in Q4 and has also committed to two years of salary to family of deceased employees due to Covid-19.
- **Increase in App downloads:** JUBI saw a healthy increase in its app downloads to 57.3mn (vs. 33.1mn at Q4FY20-end). JUBI indicated that this is an outcome of increased investment on digital assets, better experience and relatively attractive offers on own application. JUBI indicated that its own app users have higher frequency as well as higher ticket size compared to orders through aggregators.
- **No Price hikes taken:** JUBI has not taken any price increase for Domino's over the last three years. This has helped to make Dominos more affordable vs competitors and has increased its order count and new customer acquisitions. Introduction of Delivery charge added to sales/SSG last year, which will anniversarise this quarter.
- **Building organization bandwidth:** Mr Rajneesh Kohli has been appointed as chief business officer and Amit Maheshwari will be taking over the chief operations officer for Dominos. Mr Avinash Kant will be heading the integrated supply-chain. All three of them are internal elevations. Mr Gaurav Pande has been hired to develop and grow Popeyes brand in India.
- **Bangladesh/Sri Lanka Network:** JUBI opened 3/1 new stores in Sri Lanka/Bangladesh, taking total to 26/5 stores in these geographies. Both countries turned EBITDA positive in Q4FY21. JUBI sees healthy expansion scope due to underpenetration and growing acceptance of digital assets in these geographies.
- **DP Euresia Stake acquisition:** It holds the leading position in Turkey and is at No. 3/4 in Russia. JUBI plans to replicate its best practices and transfer learnings from the Indian market to these new geographies with three board seats in the company. No plans were indicated to increase further stake. JUBI acquired 32.81% stake for Rs2.6bn (GBP24.8mn).
- **New formats – Hongs/Ekdum/Popeyes:** According to JUBI, chicken is an Rs40bn segment and growing strongly at 17-18% CAGR over the last few years. JUBI intends to open its Popeyes stores in FY22E and indicated Popeyes and expect a large growth opportunity. JUBI has a commitment to open certain minimum number of stores over the next few years in the agreement (Details not divulged) but expects a quicker ramp-up. For Hongs/Ekdum it added 8 restaurants in FY21 taking total to 12 stores, including delivery/carry out stores.

Key Financials (Standalone)**Income Statement**

Y/E Mar (Rs mn)	FY20	FY21	FY22E	FY23E	FY24E
Revenue	38,858	32,689	44,710	55,500	64,514
Expenditure	30,087	25,023	33,274	40,901	47,474
EBITDA	8,771	7,666	11,436	14,599	17,041
Depreciation	3,425	3,672	3,859	4,324	4,872
EBIT	5,346	3,993	7,577	10,274	12,169
Other Income	672	704	844	1,056	1,214
Interest expenses	1,635	1,606	1,649	1,790	1,946
PBT	4,383	3,091	6,773	9,540	11,437
Tax	1,181	754	1,707	2,404	2,882
Extraordinary Items	(448)	0	0	0	0
Minority Int./Income from Assoc.	0	0	0	0	0
Reported Net Income	2,755	2,337	5,066	7,136	8,555
Adjusted PAT	3,203	2,337	5,066	7,136	8,555

Balance Sheet

Y/E Mar (Rs mn)	FY20	FY21	FY22E	FY23E	FY24E
Equity share capital	1,320	1,320	1,320	1,320	1,320
Reserves & surplus	10,510	13,652	15,405	20,032	25,551
Net worth	11,829	14,971	16,724	21,352	26,871
Minority Interest	0	0	0	0	0
Loan Funds	16,515	15,992	15,982	15,661	14,976
Net deferred tax liability	(810)	(884)	(884)	(884)	(884)
Total Liabilities	27,535	30,080	31,822	36,129	40,963
Net block	21,492	21,108	21,029	20,584	19,592
Investment	1,346	6,139	6,139	6,139	6,139
Current Assets	9,952	9,692	11,587	17,866	24,996
Cash & bank balance	6,392	5,175	7,017	13,020	19,798
Other Current Assets	370	668	734	808	889
Current liabilities & Provision	5,645	7,052	7,113	8,641	9,946
Net current assets	4,308	2,640	4,473	9,225	15,051
Misc. exp	0	0	0	0	0
Total Assets	27,535	30,080	31,822	36,129	40,963

Cash Flow

Y/E Mar (Rs mn)	FY20	FY21	FY22E	FY23E	FY24E
PBT (Ex-Other income) (NI+Dep)	3,935	3,091	6,773	9,540	11,437
Other Non-Cash items	0	0	0	0	0
Chg in working cap	438	390	9	1,251	952
Operating Cashflow	7,372	7,362	9,738	13,446	15,111
Capital expenditure	(2,364)	(1,985)	(2,268)	(2,380)	(2,380)
Free Cash Flow	5,008	5,376	7,471	11,066	12,731
Investments	1,296	(303)	0	0	0
Other Investing Cash Flow	0	0	0	0	0
Investing Cashflow	(343)	(6,075)	(1,423)	(1,324)	(1,166)
Equity Capital Raised	0	0	0	0	0
Loans Taken / (Repaid)	0	0	0	0	0
Dividend paid (incl tax)	(1,747)	(792)	(1,716)	(2,508)	(3,036)
Other Financing Cash Flow	(3,779)	(1,705)	(4,756)	(3,611)	(4,131)
Financing Cashflow	(5,528)	(2,504)	(6,472)	(6,119)	(7,167)
Net chg in cash	1,502	(1,218)	1,842	6,003	6,778
Opening cash position	4,891	6,392	5,175	7,017	13,020
Closing cash position	6,392	5,175	7,017	13,020	19,798

Source: Company, Emkay Research

Key Ratios

Profitability (%)	FY20	FY21	FY22E	FY23E	FY24E
EBITDA Margin	22.6	23.5	25.6	26.3	26.4
EBIT Margin	13.8	12.2	16.9	18.5	18.9
Effective Tax Rate	26.9	24.4	25.2	25.2	25.2
Net Margin	8.2	7.1	11.3	12.9	13.3
ROCE	48.6	37.4	56.3	62.4	57.6
ROE	25.6	17.4	32.0	37.5	35.5
RoIC	42.1	21.0	40.9	58.3	76.9

Per Share Data (Rs)	FY20	FY21	FY22E	FY23E	FY24E
EPS	24.3	17.7	38.4	54.1	64.8
CEPS	50.2	45.5	67.6	86.8	101.7
BVPS	89.6	113.4	126.7	161.8	203.6
DPS	11.0	6.0	13.0	19.0	23.0

Valuations (x)	FY20	FY21	FY22E	FY23E	FY24E
PER	130.9	179.4	82.7	58.7	49.0
P/CEPS	63.2	69.7	47.0	36.6	31.2
P/BV	35.4	28.0	25.1	19.6	15.6
EV / Sales	10.7	12.6	9.2	7.3	6.2
EV / EBITDA	47.0	53.9	36.0	27.8	23.4
Dividend Yield (%)	0.3	0.2	0.4	0.6	0.7

Gearing Ratio (x)	FY20	FY21	FY22E	FY23E	FY24E
Net Debt/ Equity	(0.6)	(0.4)	(0.5)	(0.6)	(0.8)
Net Debt/EBITDA	(0.8)	(0.8)	(0.7)	(0.9)	(1.2)
Working Cap Cycle (days)	(19.6)	(28.3)	(20.8)	(25.0)	(26.9)

Growth (%)	FY20	FY21	FY22E	FY23E	FY24E
Revenue	10.1	(15.9)	36.8	24.1	16.2
EBITDA	44.3	(12.6)	49.2	27.7	16.7
EBIT	17.4	(25.3)	89.7	35.6	18.4
PAT	(14.7)	(15.2)	116.8	40.9	19.9

Quarterly (Rs mn)	Q4FY20	Q1FY21	Q2FY21	Q3FY21	Q4FY21
Revenue	8,979	3,803	8,055	10,572	10,259
EBITDA	1,694	241	2,147	2,786	2,492
EBITDA Margin (%)	18.9	6.3	26.7	26.4	24.3
PAT	210	(726)	769	1,251	1,043
EPS (Rs)	1.6	(5.5)	5.8	9.5	7.9

Source: Company, Emkay Research

Shareholding Pattern (%)	Mar-20	Jun-20	Sep-20	Dec-20	Mar-21
Promoters	41.9	41.9	41.9	41.9	41.9
FII	30.9	36.2	37.9	39.4	40.9
DII	20.7	15.7	14.5	12.8	11.4
Public and Others	6.5	6.2	5.8	5.9	5.8

Source: Capitaline

RECOMMENDATION HISTORY TABLE

Date	Closing Price	TP	Period (months)	Rating	Analyst
25-Mar-21	2,825	2,750	12m	Buy	Ashit Desai
20-Feb-21	2,951	2,750	12m	Buy	Ashit Desai
04-Feb-21	2,825	2,750	12m	Buy	Ashit Desai
13-Nov-20	2,482	2,500	12m	Buy	Ashit Desai
03-Sep-20	2,291	2,400	12m	Buy	Ashit Desai
21-May-20	1,570	1,680	12m	Buy	Ashit Desai
14-Apr-20	1,381	1,550	12m	Buy	Ashit Desai
08-Apr-20	1,407	1,550	12m	Buy	Ashit Desai
30-Jan-20	1,826	1,930	12m	Buy	Ashit Desai
25-Dec-19	1,567	1,825	12m	Buy	Ashit Desai
22-Oct-19	1,424	1,750	12m	Buy	Ashit Desai
20-Sep-19	1,376	1,700	12m	Buy	Ashit Desai
25-Jul-19	1,168	1,470	12m	Buy	Ashit Desai
16-May-19	1,235	1,540	12m	Buy	Ashit Desai
09-Apr-19	1,419	1,540	12m	Buy	Ashit Desai
12-Mar-19	1,340	1,540	12m	Buy	Ashit Desai
30-Jan-19	1,191	1,540	12m	Buy	Ashit Desai
24-Oct-18	1,184	1,450	12m	Buy	Ashit Desai
25-Jul-18	1,387	1,520	12m	Buy	Ashit Desai

Source: Company, Emkay Research

RECOMMENDATION HISTORY CHART



Source: Bloomberg, Company, Emkay Research

Emkay Alpha Portfolio – Consumer Goods & Retail



Analyst: Ashit Desai

Contact Details

ashit.desai@emkayglobal.com
+91 22 6612 1340

Sector

Consumer Goods & Retail

Analyst bio

Ashit Desai holds a PGDM and FRM (US GARP) with 13 years of research experience on the sell side. His team currently covers 24 stocks in the Indian Consumer and Retail space.

EAP sector portfolio

Company Name	BSE200 Weight	EAP Weight	OW/UW (%)	OW/UW (bps)	EAP Weight (Normalised)
Consumer Goods & Retail	10.96	10.96	0%	0	100.00
Asian Paints	1.42	0.64	-55%	-78	5.84
Berger Paints	0.21	0.00	-100%	-21	0.00
Britannia Industries	0.54	0.54	-1%	-1	4.89
Colgate-Palmolive	0.25	0.31	25%	6	2.86
Dabur India	0.40	0.35	-13%	-5	3.16
Emami	0.14	0.17	22%	3	1.51
Godrej Consumer Products	0.34	0.36	5%	2	3.24
Hindustan Unilever	2.64	2.07	-22%	-57	18.87
ITC	2.20	2.17	-1%	-3	19.77
Marico	0.26	0.31	21%	5	2.87
Nestle India	0.75	0.60	-20%	-15	5.50
Pidilite Industries	0.33	0.00	-100%	-33	0.00
Radico Khaitan	0.00	0.38	NA	38	3.44
United Breweries	0.10	0.53	452%	43	4.83
United Spirits	0.00	0.37	NA	37	3.38
Varun Beverages	0.11	0.12	6%	1	1.05
ABFRL	0.07	0.17	160%	10	1.55
Jubilant FoodWorks	0.22	0.27	23%	5	2.43
Page Industries	0.21	0.23	6%	1	2.06
Shoppers Stop	0.00	0.00	NA	0	0.00
Titan Company	0.78	1.13	44%	34	10.28
Westlife Development	0.00	0.27	NA	27	2.45
Cash	0.00	0.00	NA	0	0.00

Source: Emkay Research

* Not under coverage: Equal Weight

■ High Conviction/Strong Over Weight ■ High Conviction/Strong Under Weight

Sector portfolio NAV

	Base						Latest
	1-Apr-19	15-Jun-20	14-Dec-20	15-Mar-21	14-May-21	14-Jun-21	
EAP - Consumer Goods & Retail	100.0	99.9	120.2	117.7	122.6	129.1	
BSE200 Neutral Weighted Portfolio (ETF)	100.0	93.6	115.8	111.5	118.6	124.1	

*Performance measurement base date 1st April 2019


Source: Emkay Research

Price Performance (%)

	1m	3m	6m	12m
EAP - Consumer Goods & Retail	5.3%	9.7%	7.5%	29.3%
BSE200 Neutral Weighted Portfolio (ETF)	4.6%	11.2%	7.1%	32.5%

Source: Emkay Research

NAV chart



Source: Emkay Research

Please see our model portfolio (Emkay Alpha Portfolio): [Nifty](#)

Please see our model portfolio (Emkay Alpha Portfolio): [SMID](#)

“Emkay Alpha Portfolio – SMID and Nifty are a supporting document to the Emkay Alpha Portfolios Report and is updated on regular intervals”

Emkay Rating Distribution

Ratings	Expected Return within the next 12-18 months.
BUY	Over 15%
HOLD	Between -5% to 15%
SELL	Below -5%

Completed Date: 16 Jun 2021 03:37:19 (SGT)
 Dissemination Date: 16 Jun 2021 03:38:19 (SGT)

Sources for all charts and tables are Emkay Research unless otherwise specified.

GENERAL DISCLOSURE/DISCLAIMER BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Emkay Global Financial Services Limited (CIN-L67120MH1995PLC084899) and its affiliates are a full-service, brokerage, investment banking, investment management and financing group. Emkay Global Financial Services Limited (EGFSL) along with its affiliates are participants in virtually all securities trading markets in India. EGFSL was established in 1995 and is one of India's leading brokerage and distribution house. EGFSL is a corporate trading member of Bombay Stock Exchange Limited (BSE), National Stock Exchange of India Limited (NSE), MCX Stock Exchange Limited (MCX-SX). EGFSL along with its subsidiaries offers the most comprehensive avenues for investments and is engaged in the businesses including stock broking (Institutional and retail), merchant banking, commodity broking, depository participant, portfolio management, insurance broking and services rendered in connection with distribution of primary market issues and financial products like mutual funds, fixed deposits. Details of associates are available on our website i.e. www.emkayglobal.com

EGFSL is registered as Research Analyst with SEBI bearing registration Number INH000000354 as per SEBI (Research Analysts) Regulations, 2014. EGFSL hereby declares that it has not defaulted with any stock exchange nor its activities were suspended by any stock exchange with whom it is registered in last five years, except that NSE had disabled EGFSL from trading on October 05, October 08 and October 09, 2012 for a manifest error resulting into a bonafide erroneous trade on October 05, 2012. However, SEBI and Stock Exchanges have conducted the routine inspection and based on their observations have issued advice letters or levied minor penalty on EGFSL for certain operational deviations in ordinary/routine course of business. EGFSL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

EGFSL offers research services to clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

Other disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report

EGFSL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that may be inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would subject EGFSL or its group companies to any registration or licensing requirement within such jurisdiction. Specifically, this document does not constitute an offer to or solicitation to any U.S. person for the purchase or sale of any financial instrument or as an official confirmation of any transaction to any U.S. person. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. No part of this document may be used by private customers in United Kingdom. All material presented in this report, unless specifically indicated otherwise, is under copyright to Emkay. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of EGFSL. All trademarks, service marks and logos used in this report are trademarks or registered trademarks of EGFSL or its Group Companies. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

- This publication has not been reviewed or authorized by any regulatory authority. There is no planned schedule or frequency for updating research publication relating to any issuer.
- Please contact the primary analyst for valuation methodologies and assumptions associated with the covered companies or price targets

Disclaimer for U.S. persons only: This research report is a product of Emkay Global Financial Services Limited (Emkay), which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of Financial Institutions Regulatory Authority (FINRA) or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account. This report is intended for distribution to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor. In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors.

ANALYST CERTIFICATION BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL)

The research analyst(s) primarily responsible for the content of this research report, in part or in whole, certifies that the views about the companies and their securities expressed in this report accurately reflect his/her personal views. The analyst(s) also certifies that no part of his/her compensation was, is, or will be, directly or indirectly, related to specific recommendations or views expressed in the report. The research analyst (s) primarily responsible of the content of this research report, in part or in whole, certifies that he or his associate¹ does not serve as an officer, director or employee of the issuer or the new listing applicant (which includes in the case of a real estate investment trust, an officer of the management company of the real estate investment trust; and in the case of any other entity, an officer or its equivalent counterpart of the entity who is responsible for the management of the issuer or the new listing applicant). The research analyst(s) primarily responsible for the content of this research report or his associate does not have financial interests² in relation to an issuer or a new listing applicant that the analyst reviews. EGFSL has procedures in place to eliminate, avoid and manage any potential conflicts of interests that may arise in connection with the production of research reports. The research analyst(s) responsible for this report operates as part of a separate and independent team to the investment banking function of the EGFSL and procedures are in place to ensure that confidential information held by either the research or investment banking function is handled appropriately. There is no direct link of EGFSL compensation to any specific investment banking function of the EGFSL.

¹ An associate is defined as (i) the spouse, or any minor child (natural or adopted) or minor step-child, of the analyst; (ii) the trustee of a trust of which the analyst, his spouse, minor child (natural or adopted) or minor step-child, is a beneficiary or discretionary object; or (iii) another person accustomed or obliged to act in accordance with the directions or instructions of the analyst.

² Financial interest is defined as interest that are commonly known financial interest, such as investment in the securities in respect of an issuer or a new listing applicant, or financial accommodation arrangement between the issuer or the new listing applicant and the firm or analysis. This term does not include commercial lending conducted at the arm's length, or investments in any collective investment scheme other than an issuer or new listing applicant notwithstanding the fact that the scheme has investments in securities in respect of an issuer or a new listing applicant.

COMPANY-SPECIFIC / REGULATORY DISCLOSURES BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report:-

1. EGFSL, its subsidiaries and/or other affiliates do not have a proprietary position in the securities recommended in this report as of June 16, 2021
2. EGFSL, and/or Research Analyst does not market make in equity securities of the issuer(s) or company(ies) mentioned in this Research Report
3. EGFSL may have published other investment recommendations in respect of the same securities / instruments recommended in this research report during the preceding 12 months. Please contact the primary analyst listed in the first page of this report to view previous investment recommendations published by EGFSL in the preceding 12 months.
4. EGFSL , its subsidiaries and/or other affiliates and Research Analyst or his/her relative's does not have any material conflict of interest in the securities recommended in this report as of June 16, 2021.
5. EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative's does not have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the June 16, 2021
6. EGFSL, its subsidiaries and/or other affiliates and Research Analyst have not received any compensation in whatever form including compensation for investment banking or merchant banking or brokerage services or for products or services other than investment banking or merchant banking or brokerage services from securities recommended in this report (subject company) in the past 12 months.
7. EGFSL, its subsidiaries and/or other affiliates and/or and Research Analyst have not received any compensation or other benefits from securities recommended in this report (subject company) or third party in connection with the research report.
8. Securities recommended in this report (Subject Company) has not been client of EGFSL, its subsidiaries and/or other affiliates and/or and Research Analyst during twelve months preceding the June 16, 2021

RESTRICTIONS ON DISTRIBUTION

General	This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation.
Australia	This report is not for distribution into Australia.
Hong Kong	This report is not for distribution into Hong Kong.
Indonesia	This report is being distributed in Indonesia by PT DBS Vickers Sekuritas Indonesia.
Malaysia	This report is not for distribution into Malaysia.
Singapore	This report is distributed in Singapore by DBS Bank Ltd (Company Regn. No. 16800306E) or DBSVS (Company Regn. No. 1860024G) both of which are Exempt Financial Advisers as defined in the Financial Advisers Act and regulated by the Monetary Authority of Singapore. DBS Bank Ltd and/or DBSVS, may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an agreement under Regulation 32C of the financial Advisers Regulations. Singapore recipients should contact DBS Bank Ltd at 6327 2288 for matters arising from, or in connection with the report.
Thailand	This report is being distributed in Thailand by DBS Vickers Securities (Thailand) Co Ltd.
United Kingdom	This report is disseminated in the United Kingdom by DBS Vickers Securities (UK) Ltd, ("DBSVUK"). DBSVUK is authorised and regulated by the Financial Conduct Authority in the United Kingdom. In respect of the United Kingdom, this report is solely intended for the clients of DBSVUK, its respective connected and associated corporations and affiliates only and no part of this document may be (i) copied, photocopied or duplicated in any form or by any means or (ii) redistributed without the prior written consent of DBSVUK. This communication is directed at persons having professional experience in matters relating to investments. Any investment activity following from this communication will only be engaged in with such persons. Persons who do not have professional experience in matters relating to investments should not rely on this communication.
Dubai International Financial Centre	This research report is being distributed by DBS Bank Ltd., (DIFC Branch) having its office at units 608-610, 6 th Floor, Gate Precinct Building 5, PO Box 506538, Dubai International Financial Centre (DIFC), Dubai, United Arab Emirates. DBS Bank Ltd., (DIFC Branch) is regulated by The Dubai Financial Services Authority. This research report is intended only for professional clients (as defined in the DFSA rulebook) and no other person may act upon it.
United Arab Emirates	This report is provided by DBS Bank Ltd (Company Regn. No. 196800306E) which is an Exempt Financial Adviser as defined in the Financial Advisers Act and regulated by the Monetary Authority of Singapore. This report is for information purposes only and should not be relied upon or acted on by the recipient or considered as a solicitation or inducement to buy or sell any financial product. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situation, or needs of individual clients. You should contact your relationship manager or investment adviser if you need advice on the merits of buying, selling or holding a particular investment. You should note that the information in this report may be out of date and it is not represented or warranted to be accurate, timely or complete. This report or any portion thereof may not be reprinted, sold or redistributed without our written consent.
United States	DBSVUSA did not participate in its preparation. The research analyst(s) named on this report are not registered as research analysts with FINRA and are not associated persons of DBSVUSA. The research analyst(s) are not subject to FINRA Rule 2241 restrictions on analyst compensation, communications with a subject company, public appearances and trading securities held by a research analyst. This report is being distributed in the United States by DBSVUSA, which accepts responsibility for its contents. This report may only be distributed to Major U.S. Institutional Investors (as defined in SEC Rule 15a-6) and to such other institutional investors and qualified persons as DBSVUSA may authorize. Any U.S. person receiving this report who wishes to effect transactions in any securities referred to herein should contact DBSVUSA directly and not its affiliate.
Other jurisdictions	In any other jurisdictions, except if otherwise restricted by laws or regulations, this report is intended only for qualified, professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions.

Emkay Global Financial Services Ltd.

CIN - L67120MH1995PLC084899

7th Floor, The Ruby, Senapati Bapat Marg, Dadar - West, Mumbai - 400028. India

Tel: +91 22 66121212 Fax: +91 22 66121299 Web: www.emkayglobal.com